Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip

743
84
Favorite

Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip

Motley Fool2022-06-24

Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

743

Report

Comment（84）

tig2021
·2022-06-27
Ok
Reply
1
Report
Phoenix5104
·2022-06-27
Hihihihi
Reply
Like
Report
Phoenix5104
·2022-06-27
Hello
Reply
1
Report
sinneDteo
·2022-06-26
Good luck everyone
Reply
2
Report
LEESIMON
·2022-06-26
ok
Reply
1
Report
Newnew
·2022-06-26
Hi
Reply
2
Report
Jess261
·2022-06-26
Okay
Reply
2
Report
jasonpstt
·2022-06-26
Ok
Reply
2
Report
toh156
·2022-06-26
Ok
Reply
Like
Report
VivianChua
·2022-06-25
Ok 👌
Reply
2
Report
Tchwee56
·2022-06-25
Like
Reply
2
Report
Tchwee56
·2022-06-25
Like
Reply
2
Report
andy1967
·2022-06-25
Okay thanks for sharing.
Reply
2
Report
来人
·2022-06-25
Ok
Reply
Like
Report
Blading23
·2022-06-25
Ok
Reply
3
Report
Mushroom88
·2022-06-25
Like
Reply
1
Report
lol269
·2022-06-25
Ok
Reply
1
Report
HengHuat
·2022-06-25
Gonna target it
Reply
1
Report
Looyusooi
·2022-06-25
Ok
Reply
1
Report
Simonnov
·2022-06-25
Ic
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1174980552?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-06-24 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174980552","market":"us","top_or_hot":-1,"title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","media":"Motley Fool","content":"<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABBV","symbol_name":"艾伯维公司","start_time":0,"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","article_id":"1174980552","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","pubTimestamp":1656084623,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"translate_title":"拿到1000美元？逢低买入这2只超高收益股息股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"TGT":0.9},"content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9048779064,"gmtCreate":1656280599458,"gmtModify":1676535795049,"author":{"id":"3587008457873110","authorId":"3587008457873110","name":"tig2021","avatar":"https://static.tigerbbs.com/86558e2c1be0fae967630b306994ef5a","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3587008457873110","authorIdStr":"3587008457873110"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048779064","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048746997,"gmtCreate":1656279444519,"gmtModify":1676535794937,"author":{"id":"3585694968236372","authorId":"3585694968236372","name":"Phoenix5104","avatar":"https://static.tigerbbs.com/f0a316ae2880cadff61373ca7d5cf06a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3585694968236372","authorIdStr":"3585694968236372"},"htmlText":"Hihihihi","listText":"Hihihihi","text":"Hihihihi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048746997","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048746046,"gmtCreate":1656279437085,"gmtModify":1676535794917,"author":{"id":"3585694968236372","authorId":"3585694968236372","name":"Phoenix5104","avatar":"https://static.tigerbbs.com/f0a316ae2880cadff61373ca7d5cf06a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3585694968236372","authorIdStr":"3585694968236372"},"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048746046","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048715517,"gmtCreate":1656259174939,"gmtModify":1676535793802,"author":{"id":"3574190598868333","authorId":"3574190598868333","name":"sinneDteo","avatar":"https://static.tigerbbs.com/120e946e020025a0f2a0ab36032d4712","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3574190598868333","authorIdStr":"3574190598868333"},"htmlText":"Good luck everyone&nbsp;","listText":"Good luck everyone&nbsp;","text":"Good luck everyone","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048715517","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048242987,"gmtCreate":1656216128049,"gmtModify":1676535787091,"author":{"id":"3579044609497336","authorId":"3579044609497336","name":"LEESIMON","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"3579044609497336","authorIdStr":"3579044609497336"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048242987","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048238817,"gmtCreate":1656210389839,"gmtModify":1676535785541,"author":{"id":"3583016139705080","authorId":"3583016139705080","name":"Newnew","avatar":"https://static.tigerbbs.com/c1f72fa81dd8aa4df22904e9ff7b7c9b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583016139705080","authorIdStr":"3583016139705080"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048238817","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048613660,"gmtCreate":1656203565251,"gmtModify":1676535783165,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048613660","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048868037,"gmtCreate":1656194866529,"gmtModify":1676535781083,"author":{"id":"3583913587299891","authorId":"3583913587299891","name":"jasonpstt","avatar":"https://static.tigerbbs.com/d55e499e6f73f06b22563034a4ad6b0b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583913587299891","authorIdStr":"3583913587299891"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048868037","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048892849,"gmtCreate":1656174989881,"gmtModify":1676535780224,"author":{"id":"4089852760719490","authorId":"4089852760719490","name":"toh156","avatar":"https://static.tigerbbs.com/1d6442864cd62fd89fbf3c33f0228ca8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4089852760719490","authorIdStr":"4089852760719490"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048892849","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048368300,"gmtCreate":1656141694500,"gmtModify":1676535776051,"author":{"id":"3580011914778910","authorId":"3580011914778910","name":"VivianChua","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3580011914778910","authorIdStr":"3580011914778910"},"htmlText":"Ok 👌","listText":"Ok 👌","text":"Ok 👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048368300","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048333830,"gmtCreate":1656136289620,"gmtModify":1676535775289,"author":{"id":"3569457005614885","authorId":"3569457005614885","name":"Tchwee56","avatar":"https://static.tigerbbs.com/cf5f966c61e6a7efe5375ef68070f8d0","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3569457005614885","authorIdStr":"3569457005614885"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048333830","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048333142,"gmtCreate":1656136283786,"gmtModify":1676535775302,"author":{"id":"3569457005614885","authorId":"3569457005614885","name":"Tchwee56","avatar":"https://static.tigerbbs.com/cf5f966c61e6a7efe5375ef68070f8d0","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3569457005614885","authorIdStr":"3569457005614885"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048333142","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048956141,"gmtCreate":1656129362883,"gmtModify":1676535774054,"author":{"id":"3577153253038717","authorId":"3577153253038717","name":"andy1967","avatar":"https://static.tigerbbs.com/4c9eab1ea6730e01c8143915e463cc57","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3577153253038717","authorIdStr":"3577153253038717"},"htmlText":"Okay thanks for sharing.&nbsp;","listText":"Okay thanks for sharing.&nbsp;","text":"Okay thanks for sharing.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048956141","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048951014,"gmtCreate":1656129190438,"gmtModify":1676535774012,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3575544575320394","authorIdStr":"3575544575320394"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048951014","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048988644,"gmtCreate":1656126408688,"gmtModify":1676535773156,"author":{"id":"3565700003213382","authorId":"3565700003213382","name":"Blading23","avatar":"https://community-static.tradeup.com/news/4cd7ba668d1c755bf79285b205abdfb2","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3565700003213382","authorIdStr":"3565700003213382"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048988644","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048914166,"gmtCreate":1656125824155,"gmtModify":1676535773017,"author":{"id":"4112443956308662","authorId":"4112443956308662","name":"Mushroom88","avatar":"https://community-static.tradeup.com/news/cc3c319d319348d2162ea1862b1ed950","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4112443956308662","authorIdStr":"4112443956308662"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048914166","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048913075,"gmtCreate":1656125320297,"gmtModify":1676535772875,"author":{"id":"4102214937557530","authorId":"4102214937557530","name":"lol269","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4102214937557530","authorIdStr":"4102214937557530"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048913075","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048935184,"gmtCreate":1656124951548,"gmtModify":1676535772769,"author":{"id":"4089527924629590","authorId":"4089527924629590","name":"HengHuat","avatar":"https://static.tigerbbs.com/5854d1323f59ffe9e66dca6d58fd6af8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089527924629590","authorIdStr":"4089527924629590"},"htmlText":"Gonna target it","listText":"Gonna target it","text":"Gonna target it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048935184","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048904278,"gmtCreate":1656123378794,"gmtModify":1676535772244,"author":{"id":"4100437715079400","authorId":"4100437715079400","name":"Looyusooi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4100437715079400","authorIdStr":"4100437715079400"},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048904278","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9048908791,"gmtCreate":1656123183013,"gmtModify":1676535772157,"author":{"id":"4097750438225520","authorId":"4097750438225520","name":"Simonnov","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4097750438225520","authorIdStr":"4097750438225520"},"htmlText":"Ic","listText":"Ic","text":"Ic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048908791","repostId":1174980552,"repostType":4,"repost":{"id":"1174980552","kind":"news","pubTimestamp":1656084623,"share":"https://ttm.financial/m/news/1174980552?lang=&edition=fundamental","pubTime":"2022-06-24 23:30","market":"us","language":"en","title":"Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1174980552","media":"Motley Fool","summary":"A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.","content":"<html><head></head><body><p>Sometimes a stock falls to levels so low, it almost doesn&#39;t matter what an investor&#39;s budget is -- they have to buy at least a few shares to take advantage of the situation. With the market&#39;s retreat lately, a great many stocks are at, or teasing, their recent low-water marks.</p><p>This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both <b>Target</b> and <b>AbbVie</b> excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of <b>S&amp;P 500</b> index stocks.</p><p><b>1. Target</b></p><p>For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.</p><p>Neither of these difficulties will melt away quickly, but at the same time, we know they&#39;re not going to linger forever.</p><p>The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let&#39;s keep in mind that Russia&#39;s apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.</p><p>With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.</p><p>Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.</p><p>Management is smart and careful, and I don&#39;t think they&#39;d pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they&#39;re confident the company&#39;s fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.</p><p><b>2. AbbVie</b></p><p>Another Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world&#39;s best-selling drug: Humira.</p><p>The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.</p><p>Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.</p><p>So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.</p><p>Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.</p><p>With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-24 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","TGT":"塔吉特"},"source_url":"https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174980552","content_text":"Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.This presents some nearly irresistible opportunities for investors, particularly if they like high-yielding dividends. As prices go down, yields go up, and that dynamic has made both Target and AbbVie excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.1. TargetFor quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble. That all came to a crashing halt with its first-quarter 2022 results.The company missed badly on the bottom line due largely to ballooning inflation and inventory issues.Neither of these difficulties will melt away quickly, but at the same time, we know they're not going to linger forever.The aggressive discounting Target has been doing to clear its excess inventory will continue to dampen its profit margins, but eventually, the company will get inventory back to its typical, more reasonable, levels. Inflation might prove to be a more stubborn headwind. However, let's keep in mind that Russia's apparently unsustainable war in Ukraine and the (hopefully fading) pandemic were two big drivers of the ongoing supply chain disruptions that are fueling that inflation.With an improving macroeconomic situation at its back, Target should return to delivering the envy-of-the-retail-sector profit margins that drew investors to its stock in recent years. At the moment, though, its forward P/E has shriveled to barely above 16, a very low number considering how effectively management cranked profitability higher in preceding quarters.Earlier this month, to help maintain its Dividend Kingstatus, Target raised its payout by 20% -- a gutsy move given the crushing disappointment of its Q1 earnings.Management is smart and careful, and I don't think they'd pull such a lever simply to keep shareholders on board, or to keep the renown conferred with Dividend King status. I feel they're confident the company's fundamentals will rebound. As they do, folks piling into the stock at current share prices will enjoy a 3.1% dividend yield. They should also have the pleasure of seeing that depressed stock rise again.2. AbbVieAnother Dividend King with a tarnished crown ispharmaceutical sectorgiant AbbVie. The company currently has the distinction of being the entity behind the world's best-selling drug: Humira.The big catch with Humira, though, is that its patent protection expires next year, so the Mississippi River-sized revenue stream that it has historically produced will thin out quickly as it starts competing with biosimilars.Yet AbbVie is far more than just one product. Two of its more recently approved drugs -- Skyrizi and Rinboq, developed as replacements for Humira -- together brought in over $4.5 billion in sales last year. That amounted to growth of more than 80% over the 2020 figure. Smart acquisitions, like that of Botox maker Allergan in 2020, have also beefed up its portfolio.So the AbbVie growth train keeps barreling along. Thanks to those blockbusters and the acquisitions, its revenue nearly doubled from 2017 to 2021, landing at over $56 billion. Net profit, meanwhile, more than doubled over that stretch to almost $11.5 billion.Like the best high-potential drug developers, AbbVie has a pipeline that is wide and deep. The company has a dizzying number of programs covering a range of maladies. Oncology is a particular strength, and the company is active in other high-interest areas such as immunology, neuroscience, and virology.With the erosion of its share price -- more due to general market gloominess than anything else -- AbbVie is now a high-yield superstar in the healthcare sector. Its quarterly payout of $1.41 amounts to a yield of over 4%, trouncing even the bluest of the blue chip stocks in other industries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":743,"commentSize":84,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}